Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2014 (2014), Article ID 563243, 4 pages
http://dx.doi.org/10.1155/2014/563243
Clinical Study

Maternal Characteristics Influencing the Development of Gestational Diabetes in Obese Women Receiving 17-alpha-Hydroxyprogesterone Caproate

1Department of Obstetrics and Gynecology, University of Florida College of Medicine, 1600 SW Archer Road, P.O. Box 100294, Gainesville, FL 32610-0294, USA
2University of Tennessee Health Science Center, Memphis, TN 38163, USA
3Department of Clinical Research, Alere, Women’s & Children’s Health, Atlanta, GA 30339, USA

Received 30 May 2014; Revised 22 September 2014; Accepted 2 October 2014; Published 27 October 2014

Academic Editor: Eric Doucet

Copyright © 2014 Robert Egerman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Committee on Practice Bulletins-Obstetrics and The American College of Obstetricians and Gynecologists, “Practice bulletin no. 130: prediction and prevention of preterm birth,” Obstetrics & Gynecology, vol. 120, no. 4, pp. 964–973, 2012. View at Google Scholar
  2. J. M. O'Brien, E. A. DeFranco, C. D. Adair et al., “Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial,” Ultrasound in Obstetrics & Gynecology, vol. 34, no. 6, pp. 653–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. E. A. DeFranco, J. M. O'Brien, C. D. Adair et al., “Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial,” Ultrasound in Obstetrics and Gynecology, vol. 30, no. 5, pp. 697–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. S. Hassan, R. Romero, D. Vidyadhari et al., “Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial,” Ultrasound in Obstetrics and Gynecology, vol. 38, no. 1, pp. 18–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Iams, “Prevention of preterm parturition,” The New England Journal of Medicine, vol. 370, no. 3, pp. 254–261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Rebarber, N. B. Istwan, K. Russo-Stieglitz et al., “Increased incidence of gestational diabetes in women receiving prophylactic 17α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery,” Diabetes Care, vol. 30, no. 9, pp. 2277–2280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. P. Waters, B. A. H. Schultz, B. M. Mercer, and P. M. Catalano, “Effect of 17α-hydroxyprogesterone caproate on glucose intolerance in pregnancy,” Obstetrics and Gynecology, vol. 114, no. 1, pp. 45–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Gyamfi, A. L. Horton, V. Momirova et al., “The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies,” The American Journal of Obstetrics & Gynecology, vol. 201, no. 4, pp. 392.e1–392.e5, 2009. View at Google Scholar
  9. K. M. Flegal, M. D. Carroll, C. L. Ogden, and L. R. Curtin, “Prevalence and trends in obesity among US adults, 1999–2008,” The Journal of the American Medical Association, vol. 303, no. 3, pp. 235–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. American College of Obstetricians and Gynecologists, “ACOG Committee opinion no. 549: ‘obesity in pregnancy’,” Obstetrics & Gynecology, vol. 121, no. 1, pp. 213–217, 2013. View at Google Scholar
  11. P. J. Meis, M. Klebanoff, E. Thom et al., “Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate,” The New England Journal of Medicine, vol. 348, no. 24, pp. 2379–2385, 2003. View at Google Scholar
  12. B. M. Sibai, N. B. Istwan, B. Palmer, and G. J. Stanziano, “Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011,” American Journal of Perinatology, vol. 29, no. 8, pp. 635–642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Regenstein, J. Belluomini, and M. Katz, “Terbutaline tocolysis and glucose intolerance,” Obstetrics and Gynecology, vol. 81, no. 5I, pp. 739–741, 1993. View at Google Scholar · View at Scopus
  14. D. D. Brǎnişteanu and C. Mathieu, “Progesterone in gestational diabetes mellitus: guilty or not guilty?” Trends in Endocrinology and Metabolism, vol. 14, no. 2, pp. 54–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Picard, M. Wanatabe, K. Schoonjans, J. Lydon, B. W. O'Malley, and J. Auwerx, “Progesterone receptor knockout mice have an improved glucose homeostasis secondary to β-cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15644–15648, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. B. E. Metzger, L. P. Lowe, A. R. Dyer et al., “Hyperglycemia and adverse pregnancy outcomes,” The New England Journal of Medicine, vol. 358, no. 19, pp. 1991–2002, 2008. View at Publisher · View at Google Scholar
  17. B. E. Metzger, L. P. Lowe, A. R. Dyer et al., “Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations with neonatal anthropometrics,” Diabetes, vol. 58, no. 2, pp. 453–459, 2009. View at Publisher · View at Google Scholar · View at Scopus